



RealRate

## PHARMACEUTICAL 2018











## PHARMACEUTICAL 2018



## REGENERON PHARMACEUTICALS INC.



Rank 54 of 342

The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 107% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 207%, being 161% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	4,335,030
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,135,483
Liabilities, Non-Current	152,073
Other Assets	2,070,651
Other Compr. Net Income	13,480
Other Expenses	1,277,061
Other Liabilities	1,332,652
Other Net Income	-1,080
Other Revenues	5,872,227
Property and Equipment	2,358,605
Research and Development	2,075,142
Selling, General and Administrative Expense	1,320,433

Output Variable	Value in 1000 USD
Assets	8,764,286
Liabilities	2,620,208
Expenses	4,672,636
Revenues	5,872,227
Stockholders Equity	6,144,078
Net Income	1,198,511
Comprehensive Net Income	1,205,251
Economic Capital Ratio	207%

